Department of Neurosurgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
Department of Neurosurgery, Kohsei Chuo General Hospital, Tokyo, Japan.
Brain Tumor Pathol. 2019 Oct;36(4):144-151. doi: 10.1007/s10014-019-00351-0. Epub 2019 Sep 5.
The study aim to demonstrate the therapeutic tissue depth of photodynamic therapy (PDT) using the photosensitizer talaporfin sodium and semiconductor laser for malignant glioma from an autopsy finding. Three patients diagnosed with glioblastoma by pre-operative imaging (1 newly diagnosed patient and 2 patients with recurrence) were treated with intra-operative additional PDT and adjuvant therapy such as post-operative radiotherapy or chemotherapy. All three patients died of brain stem dysfunction owing to cerebrospinal fluid dissemination or direct invasion of the tumor cells from 13, 18, or 20 months after PDT. Antemortem magnetic resonance images demonstrated no tumor recurrence in the site of PDT, and autopsy was performed for the pathological analysis. Macroscopic observation demonstrated no tumor recurrence in two patients, but one patient demonstrated tumor recurrence in the therapeutic depth of PDT. Microscopic analysis demonstrated histopathological changes reaching depths of 9, 11, and 18 mm (mean: 12.7 mm) from the surface of the cavity of tumor resection, suggesting the therapeutic tissue depth of PDT to be in this range. This region demonstrated glial scarring with infiltration of T lymphocytes and macrophages, with slight degeneration of small vessel walls. However, viable tumor tissues were observed beyond or around the therapeutic tissue depth of PDT in two patients. PDT for glioblastoma prevented early local recurrence, which suggests the possibility that activation of the immune mechanisms was involved. The therapeutic tissue depth was suggested to be 9-18 mm from the surface of the cavity of tumor resection; however, the viable tumor tissues were demonstrated beyond this therapeutic range.
本研究旨在通过光动力疗法(PDT)使用光敏剂替拉扎明钠和半导体激光治疗恶性脑胶质瘤,从尸检结果中展示治疗组织深度。三名经术前影像学诊断为胶质母细胞瘤的患者(1 例新诊断患者和 2 例复发患者)接受了术中额外的 PDT 治疗和辅助治疗,如术后放疗或化疗。所有三名患者均因脑干细胞功能障碍而死亡,原因是肿瘤细胞从 PDT 后 13、18 或 20 个月脑脊液扩散或直接侵犯。生前磁共振成像显示 PDT 部位无肿瘤复发,进行尸检进行病理分析。宏观观察显示两名患者无肿瘤复发,但一名患者在 PDT 的治疗深度显示肿瘤复发。微观分析显示从肿瘤切除腔表面深度为 9、11 和 18mm(平均值:12.7mm)的组织学变化,提示 PDT 的治疗组织深度在此范围内。该区域表现为伴有 T 淋巴细胞和巨噬细胞浸润的神经胶质瘢痕,小血管壁有轻微变性。然而,在两名患者中,在 PDT 的治疗组织深度之外或周围观察到存活的肿瘤组织。替拉扎明钠治疗胶质母细胞瘤可预防早期局部复发,这提示免疫机制的激活可能参与其中。治疗组织深度从肿瘤切除腔表面推测为 9-18mm,但在该治疗范围之外显示出存活的肿瘤组织。